Healthcare

July 16, 2019

1

AHF: Clock Is Ticking, WHO – Act Now on Ebola!

With the first reported case of Ebola emerging this week in Goma, a populous city in the eastern Democratic Republic of the Congo (DRC) next to the Rwandan city of Gisenyi, medical care providers and public health advocates from AIDS Healthcare Foundation (AHF) are speaking out loudly—declaring"...

Continue Reading >

July 16, 2019

2

ResMed Inc. Completes $500M Private Placement Debt Offering

ResMed Inc. (NYSE: RMD, ASX: RMD) announced today the successful pricing and closing of a private placement offering of $250,000,000 principal amount 3.24% senior notes due July 10, 2026, and $250,000,000 principal amount 3.45% senior notes due July 10, 2029.

Net proceeds from the offering will be approximately $498 million, after deducting estimated fees and expenses related to the offering. The net proceeds will be used to pay down current borrowings"...

Continue Reading >

July 16, 2019

3

CosmeSurge, the pioneer in aesthetic services, launches its 15th clinic

CosmeSurge, one of the region’s most trusted brands for cosmetic and aesthetic procedures, has launched its 15th centre in the UAE and Oman. Located on the second floor of Bareen International Hospital in Mohammed Bin Zayed City, Abu Dhabi, the centre will provide innovative, high quality aesthetic and cosmetic dermatology and plastic surgery services for which the brand is renowned.

NMC Health’s Chief Operating Officer Michael Davis"...

Continue Reading >

July 16, 2019

4

SpeeDx Receives Clearance from Health Canada for ResistancePlus® MG Test

SpeeDx Pty. Ltd. today announced ResistancePlus® MG has been cleared by Health Canada and is now available for sale across all Canadian provinces (not currently available in the U.S.). The molecular diagnostic test detects the sexually transmitted infection (STI) Mycoplasma genitalium, also known as Mgen, along with genetic markers linked to antibiotic resistance. This is the first commercially available test in Canada combining identification and therapeutic guidance information to support Resistance Guided Therapy for"...

Continue Reading >

July 16, 2019

5

New Study Investigates the Utility of Masimo ORi™, Oxygen Reserve Index, As an Indicator to Avoid Hyperoxia During General Anesthesia

Masimo (NASDAQ: MASI) announced today that in a study recently published in the Journal of Clinical Monitoring and Computing, researchers investigated the ability of Masimo ORi™ (Oxygen Reserve Index) to serve as a noninvasive indicator of the arterial partial pressure of oxygen (PaO2) during"...

Continue Reading >

July 15, 2019

6

Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform

Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month. Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with"...

Continue Reading >

July 11, 2019

7

Morinaga Milk’s Probiotic Bifidobacterium longum BB536 Achieves Self-Affirmed GRAS for Infants in Celebration of Its 50th Anniversary

Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic Morinaga Bifidobacterium longum BB536 has received self-affirmed GRAS (Generally Recognized as Safe) for infant formulas, in honor of its 50th anniversary. Bifidobacterium longum BB536, a clinically proven multifunctional probiotic strain that was originated from the gut of a healthy breast-fed infant in 1969, is celebrating its 50th anniversary of its discovery in 2019. The probiotic strain Bifidobacterium longum BB536 had previously attained official confirmation from the U.S. Food and Drug Administration (FDA) and was recognized as safe and suitable for use in a variety of food products and dietary supplements (GRAS Notice No. GRN 000268). With this newest self-affirmed GRAS status, Morinaga Milk is now expanding the opportunities of its flagship probiotic......

Continue Reading >

July 11, 2019

8

Takeda Continues Ongoing Inclusion in the FTSE4Good Developed Index & MSCI ESG Leaders Index

Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) today announced that it has been selected for the 15th consecutive year by the FTSE4Good Developed Index, one of the world’s premier indices for Socially Responsible Investment (SRI), created by FTSE Russell.* In addition, Takeda was named to the MSCI ESG Leaders Index for the 10th consecutive year. Both indices target companies demonstrating the strongest environmental, social and governance (ESG) practices. Takeda has been highly recognized for strengthening its ESG business practices and information disclosure, particularly regarding its proactive management of environmental issues, as well as its Access to Medicines Strategy, which seeks to help address the unmet needs of patients in underserved communities around the world. Takeda ranked fifth in the 2018 Access to Medicine Index, climbing 10 places......

Continue Reading >

July 11, 2019

9

GVK BIO Announces Appointment of Robert R. Ruffolo, Ph.D., to its Board of Directors

GVK BIO is pleased to announce the appointment of Dr. Robert (Bob) R. Ruffolo, to its Board of Directors.

“On behalf of GVK BIO and its Board of Directors, I am pleased to welcome Dr. Robert Ruffolo to the Board,” stated Davinder Singh Brar, Chairman GVK BIO. “With a career spanning over four decades in the Pharmaceutical industry, Bob is an accomplished leader with a rare blend of scientific expertise, strategic thought and commercial"...

Continue Reading >

July 10, 2019

10

The Lancet Publishes: More Than 936 Million Have Obstructive Sleep Apnea Worldwide

More than 936 million people have obstructive sleep apnea – the disease’s first prevalence update in more than a decade – according to The Lancet Respiratory Medicine, the world’s leading journal in its field. The Lancet today published a multinational analysis by ResMed (NYSE: RMD) (ASX: RMD) and 12 academic leaders in sleep research. The results were first presented at the ATS 2018 International Conference in San Diego. This figure is nearly 10 times greater than the World Health Organization’s 2007 estimate of more than 100 million, renewing calls for physicians to step up their efforts to screen, diagnose, and prescribe treatment for those who unknowingly suffer. “More than 85 percent of sleep apnea patients are undiagnosed, meaning hundreds of millions repeatedly suffocate instead of getting healthy, restful sleep each night,” said Carlos M.......

Continue Reading >


Forex News Headline



Forex Market Video